Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | REN | P00797 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531036 | 0.90 | SLC6A2 (0.75) | SLC6A2OPRM1OPRD1REN | |
| SCHEMBL29530910 | 0.90 | SLC6A2 (0.75) | SLC6A2OPRM1OPRD1REN | |
| SCHEMBL29576785 | 0.90 | SLC6A2 (0.74) | SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL29471736 | 0.88 | SLC6A2 (0.63) | SLC6A2OPRM1OPRD1 | |
| SCHEMBL29353395 | 0.88 | SLC6A2 (0.77) | SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL30423227 | 0.88 | OPRM1 (0.74) | SLC6A2OPRM1OPRD1 | |
| SCHEMBL29571797 | 0.88 | OPRM1 (0.74) | SLC6A2OPRM1OPRD1 | |
| Endomorphin 2 SCHEMBL13252092 | 0.87 | OPRM1 (0.76) | OPRM1OPRD1OPRK1 | |
| Endomorphin 2 SCHEMBL22649436 | 0.87 | OPRM1 (0.76) | OPRM1OPRD1OPRK1 | |
| Endomorphin 2 SCHEMBL29577635 | 0.87 | OPRM1 (0.76) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084021-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR HIDRADENITIS SUPPURATIVA | ANAPTYSBIO, INC. | 2024-03-14 | — | — | US | claimed |
| US-20230272092-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR ICHTHYOSIS | ANAPTYSBIO, INC. | 2023-08-31 | — | — | US | claimed |
| CN-116406295-A | Anti-interleukin 36 receptor (IL-36R) therapy against ichthyosis | 安奈普泰斯生物有限公司 | 2023-07-07 | — | — | CN | claimed |
| EP-4188441-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR ICHTHYOSIS | AnaptysBio, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| CN-115925932-A | Antibodies against interleukin 36 receptor (IL-36R) | 安奈普泰斯生物有限公司 | 2023-04-07 | — | — | CN | claimed |
| WO-2022150644-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR ACNE | ANAPTYSBIO, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022150642-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR HIDRADENITIS SUPPURATIVA | ANAPTYSBIO, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022026832-A9 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR ICHTHYOSIS | ANAPTYSBIO, INC. (US) | 2022-03-24 | — | — | WO | claimed |
| WO-2022026832-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR ICHTHYOSIS | ANAPTYSBIO, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026829-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR SKIN TOXICITY | ANAPTYSBIO, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| CN-117285644-B | Phase change regulating element and application thereof | 清华大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-116583298-B | PD-1 targeted IL-15/IL-15RαFC fusion proteins with improved properties | 基因泰克公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260022181-A1 | ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R) | ANAPTYSBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12421300-B2 | Preparation method and application of single-chain antibody fragment targeting SARS-CoV-2 nucleocapsid protein | NANJING UNIVERSITY (CN) | 2025-09-23 | — | — | US | disclosed |
| CN-114044825-A | anti-Siglec-8 antibodies and methods of use thereof | 爱乐科斯公司 | 2022-02-15 | — | — | CN | disclosed |
| WO-2022026832-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR ICHTHYOSIS | ANAPTYSBIO, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022026829-A1 | ANTI-INTERLEUKIN 36 RECEPTOR (IL-36R) THERAPY FOR SKIN TOXICITY | ANAPTYSBIO, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| CN-107074948-B | Antibodies that bind AXL | 根马布股份公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113980128-A | Anti-human glycocholic acid monoclonal antibody and application thereof | 中元汇吉生物技术股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | LDLR, CHRNG, FCGR2A | SLC6A2 2979/4885OPRM1 1870/4885OPRD1 2802/4885 |
| US-20260022181-A1 | ANTIBODIES DIRECTED AGAINST INTERLEUKIN 36 RECEPTOR (IL-36R) | IL36G, IGLV6-57, IL23R | SLC6A2 3212/4885OPRM1 2227/4885OPRD1 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.